Endocrinology is among the most documentation-intensive and billing-complex specialties in outpatient medicine. Unlike many specialties where billing revolves around a predictable set of procedures, endocrinology practices manage an exceptionally wide range of chronic and acute hormonal conditions — each with its own ICD-10 coding requirements, each with distinct payer rules, and each with documentation standards that directly determine whether a claim pays or denies.
Diabetes alone accounts for a significant portion of endocrinology revenue — and diabetes billing requires coding every complication with full specificity, managing continuous glucose monitoring codes correctly, documenting self-management education appropriately, and now navigating the rapidly evolving GLP-1 medication landscape where coverage rules differ by indication, by insurer, and by year.
Add thyroid disorder management, adrenal and pituitary conditions, metabolic bone disease, obesity treatment, and a growing remote monitoring and telehealth component — and endocrinology billing becomes a specialty where even small documentation or coding gaps compound into significant revenue loss over time.
In 2026, several important updates directly affect endocrinology billing — including a new ICD-10 code for Type 2 diabetes in remission, a new CPT code for automated CGM data transmission, expanded Medicare CGM coverage, and evolving GLP-1 medication coverage rules every endocrinology practice needs to understand.
This guide covers the complete endocrinology billing and coding framework for 2026 — organized by condition and service type, with 2026 updates, state-specific notes for Illinois and Florida, and the top denial patterns to eliminate from your billing workflow.
Part 1: Diabetes Billing — The Foundation of Endocrinology Revenue
Diabetes is the most commonly managed condition in endocrinology and the most frequently miscoded. The single most important rule in diabetes billing applies to every encounter:
Always code diabetes with its complication. Never use an unspecified diabetes code when a more specific one is available.
Unspecified diabetes codes (E11.9, E10.9) are among the leading causes of audit findings and underpayments in endocrinology. Payers use HCC (Hierarchical Condition Category) risk adjustment — and specific complication codes are required to accurately capture disease severity and support appropriate reimbursement.
ICD-10-CM Diabetes Coding — Complete Specificity Required
Type 1 Diabetes Mellitus (E10 series):
| Code | Description |
|---|---|
| E10.10 | Type 1 diabetes with diabetic nephropathy, unspecified |
| E10.21 | Type 1 diabetes with diabetic nephropathy |
| E10.22 | Type 1 diabetes with diabetic CKD — link with appropriate N18 stage code |
| E10.311 | Type 1 diabetes with unspecified diabetic retinopathy with macular edema |
| E10.40 | Type 1 diabetes with diabetic neuropathy, unspecified |
| E10.41 | Type 1 diabetes with diabetic mononeuropathy |
| E10.42 | Type 1 diabetes with diabetic polyneuropathy |
| E10.51 | Type 1 diabetes with diabetic peripheral angiopathy without gangrene |
| E10.610 | Type 1 diabetes with hypoglycemia with coma |
| E10.649 | Type 1 diabetes with hypoglycemia without coma |
| E10.65 | Type 1 diabetes with hyperglycemia |
Type 2 Diabetes Mellitus (E11 series):
| Code | Description |
|---|---|
| E11.21 | Type 2 diabetes with diabetic nephropathy |
| E11.22 | Type 2 diabetes with diabetic CKD — always link with appropriate N18 stage |
| E11.29 | Type 2 diabetes with other diabetic kidney complication |
| E11.311 | Type 2 diabetes with unspecified diabetic retinopathy with macular edema |
| E11.40 | Type 2 diabetes with diabetic neuropathy, unspecified |
| E11.42 | Type 2 diabetes with diabetic polyneuropathy |
| E11.51 | Type 2 diabetes with diabetic peripheral angiopathy without gangrene |
| E11.610 | Type 2 diabetes with hypoglycemia with coma |
| E11.649 | Type 2 diabetes with hypoglycemia without coma |
| E11.65 | Type 2 diabetes with hyperglycemia |
| E11.A | Type 2 diabetes without complications, in remission (NEW — FY2026) |
New ICD-10 Code — E11.A (Effective October 1, 2025): This is one of the most significant endocrinology-specific ICD-10 additions in years. Code E11.A is assigned when the provider explicitly documents that the patient’s Type 2 diabetes is “in remission.” Critical distinction:
- “In remission” → assign E11.A
- “Resolved” → do not assign E11.A; query the provider for clarification
- Partial vs. complete remission terminology should also be clarified with the provider before coding
Other important diabetes ICD-10 codes:
| Code | Description |
|---|---|
| E08 | Diabetes mellitus due to underlying condition |
| E09 | Drug or chemical induced diabetes mellitus |
| E13 | Other specified diabetes mellitus |
| Z79.4 | Long-term (current) use of insulin — always add when applicable |
| Z79.84 | Long-term (current) use of oral hypoglycemic drugs — add when applicable |
Diabetes E/M Documentation — Supporting Higher MDM Levels
Endocrinology E/M visits for diabetes frequently support moderate to high complexity Medical Decision Making (MDM) — which justifies 99214 and 99215. The documentation that supports these levels includes:
- Multiple chronic conditions addressed — diabetes plus hypertension, CKD, retinopathy, or neuropathy in the same visit supports higher MDM
- Prescription drug management — adjustments to insulin dosing, GLP-1 dosing, or adding/changing oral agents directly support moderate or high complexity MDM
- Review of external test results — reviewing CGM reports, HbA1c trends, or nephrology lab results supports the data element of MDM
- Risk of complications — prescription drug management for a patient with unstable diabetes or hypoglycemic episodes supports higher risk levels
Document medication titration in detail in every note. A single sentence noting “insulin dose adjusted” does not adequately support MDM. The note should specify the prior dose, the new dose, the clinical reasoning for the adjustment, and the follow-up plan.
Part 2: Continuous Glucose Monitoring (CGM) Billing — The Highest-Risk Code Area in Endocrinology
CGM billing is simultaneously the most valuable and the most frequently miscoded revenue area in endocrinology. Three codes cover CGM services — and selecting the wrong one is one of the most common denial triggers in the specialty.
The Three CGM CPT Codes — How to Choose Correctly
| Code | Description | Who Bills It | Key Requirement |
|---|---|---|---|
| 95249 | Patient-owned CGM — device hook-up and patient training, physician interpretation | Physician / practice | Patient owns the device; device ownership must be confirmed before billing |
| 95250 | Ambulatory professional CGM — sensor placement, data collection (minimum 72 hours), physician interpretation | Physician / practice | Physician places sensor and interprets data; minimum 72 hours of data |
| 95251 | CGM data analysis and interpretation — ongoing ambulatory glucose monitoring review | Physician / practice | Requires formal written interpretation and report in the medical record |
The most common CGM coding mistake: Billing 95251 for a service that was actually 95249 or 95250 — or billing 95249 when the patient does not own the device. Device ownership must be confirmed prior to billing 95249 or 95250.
95251 documentation requirement: Every time 95251 is billed, the medical record must contain a formal CGM interpretation note — not just a reference to a CGM report being reviewed. The note must include the physician’s interpretation of the glucose data, identification of patterns, clinical conclusions, and the impact on the management plan.
New 2026 — CPT 99445: Automated CGM Data Collection and Transmission
Effective 2026, CPT 99445 covers the automated collection and transmission of physiologic data — including CGM glucose data collected through remote monitoring platforms. This is distinct from 95251 (which covers the physician interpretation) — 99445 covers the data collection and transmission infrastructure.
- Requires automated transmission — manually submitted patient logs do not qualify
- Average Medicare allowance for 99445: approximately $47 per 30-day period
- The transmission must occur automatically from the device — patient-initiated data sharing does not qualify
CPT 99454 — Remote Monitoring Device Supply Fee
CPT 99454 is a separate code from 99445 and covers the device supply fee for remote physiologic monitoring — including CGM devices and related supplies used in the remote monitoring workflow.
- Covers the device/supply component of remote monitoring — separate from the data transmission (99445) and interpretation (95251) components
- Requires a minimum of 2–15 days of data transmitted per 30-day billing cycle
- When the monitoring period meets this threshold, 99454 is billable alongside 99445 for the same patient in the same month
- Do not confuse the 2–15 day data requirement for 99454 with the requirements for 99445 — they are separate codes billed for separate components of the same remote monitoring service
CGM Remote Monitoring Workflow — 2026 Best Practice
For endocrinology practices using a CGM remote monitoring platform:
- Confirm automated data transmission is active for each enrolled patient
- Track transmission days — minimum 2–15 days per 30-day period must be met for 99454
- Physician reviews CGM data and completes a formal interpretation note — this triggers 95251
- Bill 99445 for the automated data collection component
- Bill 99454 for the device supply when transmission minimums are met
- Document all steps in the patient record with dates
Medicare CGM Coverage — Expanded in 2026
Medicare has broadened CGM coverage eligibility. Key Medicare CGM coverage rules:
- Every 6 months following initial CGM prescription, the treating physician must conduct an in-person or Medicare-approved telehealth visit to document adherence to the CGM regimen and diabetes treatment plan — failure to document this visit can result in CGM supply claims being denied
- When a CGM device (E2102 or E2103) is covered, the related supply allowance (A4238 or A4239) is also covered
- CGM supplies for a device integrated into an external insulin infusion pump are covered when the patient meets both CGM coverage criteria AND insulin infusion pump coverage criteria
Part 3: Thyroid Disorder Billing
Thyroid conditions are the second most common category of endocrinology encounters after diabetes. Accurate coding requires specificity in both the diagnosis and the procedure.
Thyroid ICD-10 Codes — Most Commonly Used
| Code | Description |
|---|---|
| E04.0 | Nontoxic diffuse goiter |
| E04.1 | Nontoxic single thyroid nodule |
| E04.2 | Nontoxic multinodular goiter |
| E05.00 | Thyrotoxicosis with diffuse goiter, without thyrotoxic crisis |
| E05.10 | Thyrotoxicosis with toxic single thyroid nodule |
| E05.20 | Thyrotoxicosis with toxic multinodular goiter |
| E03.9 | Hypothyroidism, unspecified |
| E03.0 | Congenital hypothyroidism with diffuse goiter |
| E06.3 | Autoimmune thyroiditis (Hashimoto’s) |
| E06.0 | Acute thyroiditis |
| C73 | Malignant neoplasm of thyroid gland |
| D09.3 | Carcinoma in situ of thyroid and other endocrine glands |
| Z80.41 | Family history of malignant neoplasm of ovary — often relevant for thyroid cancer risk |
| Z85.850 | Personal history of malignant neoplasm of thyroid — post-treatment surveillance |
Thyroid Procedure CPT Codes
| Code | Description |
|---|---|
| 60100 | Core needle biopsy of thyroid |
| 60200 | Excision of cyst or adenoma of thyroid |
| 76536 | Ultrasound of head and neck soft tissue (thyroid, parathyroid, parotid) |
| 76942 | Ultrasound guidance for needle placement — used with FNA or biopsy |
| 10005 | Fine needle aspiration (FNA), first lesion, with ultrasound guidance |
| 10006 | Fine needle aspiration, each additional lesion, with ultrasound guidance |
| 10021 | Fine needle aspiration, first lesion, without imaging guidance |
Critical coding rule for thyroid FNA: When ultrasound guidance is used during FNA, bill 10005 (FNA with ultrasound guidance) — not 10021 (without guidance). Never bill 76942 separately when it is inherently included in 10005. If the physician performs the ultrasound separately to evaluate the thyroid before deciding to biopsy, and documents it as a separate service, 76536 may be billable with Modifier 59.
Thyroid Laboratory Codes
| Test | CPT Code |
|---|---|
| Thyroid stimulating hormone (TSH) | 84443 |
| Thyroxine (T4) free | 84439 |
| Thyroxine (T4) total | 84436 |
| Triiodothyronine (T3) free | 84481 |
| Triiodothyronine (T3) total | 84480 |
| Thyroid peroxidase antibody (anti-TPO) | 86200 |
| Thyroglobulin | 84432 |
| Thyroglobulin antibody | 86800 |
| Calcitonin | 82308 |
Part 4: Other Endocrine Condition Billing
Adrenal and Pituitary Disorders
| Condition | Key ICD-10 Code | Key CPT/Lab Code |
|---|---|---|
| Primary adrenal insufficiency (Addison’s) | E27.1 | 82533 (cortisol total), 82024 (ACTH) |
| Cushing’s syndrome | E24.0–E24.9 | 82533, 82024, 24-hour urine free cortisol |
| Hyperaldosteronism | E26.01, E26.09 | 82088 (aldosterone), 82530 (cortisol, urine) |
| Hypopituitarism | E23.0 | 83519 (IGF-1), 80418 (pituitary function panel) |
| Acromegaly | E22.0 | 83519 (IGF-1 / somatomedin) |
| Prolactinoma | E22.1 | 84146 (prolactin) |
| Diabetes insipidus | E23.2 | 84600 (osmolality, urine), 80069 (renal panel) |
Metabolic Bone Disease — Osteoporosis
| Code | Description |
|---|---|
| M81.0 | Age-related osteoporosis without current pathological fracture |
| M80.00XA | Age-related osteoporosis with current pathological fracture, unspecified site |
| M85.80 | Other specified disorders of bone density and structure |
| Z82.61 | Family history of arthritis |
| 77080 | Dual-energy X-ray absorptiometry (DEXA) — axial skeleton (hips and spine) |
| 77081 | DEXA — appendicular skeleton (peripheral) |
| J0897 | Denosumab injection (Prolia/Xgeva) |
| J3489 | Zoledronic acid injection (Reclast) |
DEXA scan coding rule: DEXA scans are covered by Medicare for women aged 65+ and for patients with risk factors such as vertebral abnormalities, long-term glucocorticoid therapy, primary hyperparathyroidism, and fracture monitoring. Document the clinical indication — Medicare will deny DEXA claims without clear medical necessity documentation in the record.
Obesity and Anti-Obesity Medications (AOMs)
Obesity management has become one of the most clinically significant and billing-complex areas in endocrinology, driven by the explosion of GLP-1 receptor agonist therapies.
Obesity ICD-10 codes:
| Code | Description |
|---|---|
| E66.01 | Morbid (severe) obesity due to excess calories |
| E66.09 | Other obesity due to excess calories |
| E66.9 | Obesity, unspecified |
| Z68.30–Z68.45 | Body mass index (BMI) range codes — always add to support obesity coding |
Intensive Behavioral Therapy (IBT) for Obesity:
| Code | Description | Rate |
|---|---|---|
| G0447 | Intensive behavioral therapy for obesity, per 15 minutes | ~$28–$35 |
Medicare covers G0447 for beneficiaries with a BMI ≥ 30 kg/m². The service must be furnished by a primary care physician or qualified clinician and must follow a structured program — not just diet counseling at a routine visit.
GLP-1 Receptor Agonists — 2026 Medicare Coverage Rules:
This is one of the most important and most frequently misunderstood areas in endocrinology billing in 2026. Medicare coverage for GLP-1 medications varies by indication — the same drug may be covered for one condition and not another:
| Medication | Brand | Covered by Medicare For | NOT Covered by Medicare For |
|---|---|---|---|
| Semaglutide (injection) | Ozempic | Type 2 diabetes management | Obesity-only (no diabetes diagnosis) |
| Semaglutide (injection) | Wegovy | Cardiovascular disease risk reduction (approved 2024) | Weight loss alone without CVD indication |
| Tirzepatide | Mounjaro | Type 2 diabetes management | Obesity-only (no diabetes) |
| Tirzepatide | Zepbound | Obstructive sleep apnea (covered by Medicare January 2025) | Obesity-only without sleep apnea diagnosis |
| Liraglutide | Victoza | Type 2 diabetes management | Obesity-only |
| Liraglutide | Saxenda | Weight management | NOT currently covered by Medicare Part D for obesity |
The critical billing rule for GLP-1s: Medicare Part D currently does not cover GLP-1 medications labeled exclusively for weight loss under its 2003 statutory exclusion for weight loss drugs. However, the same molecule may be covered when prescribed for a covered indication (diabetes, cardiovascular disease, sleep apnea). Always verify the specific drug name, approved indication, and Medicare coverage status before prescribing and billing. Using the wrong diagnosis to support a GLP-1 claim is a compliance violation.
Commercial payers vary significantly on GLP-1 coverage for obesity — verify each plan’s current formulary and prior authorization requirements before initiating treatment.
Part 5: Diabetes Self-Management Education and Medical Nutrition Therapy
These services represent significant missed revenue in most endocrinology practices. They are already being provided — but rarely captured with the correct billing codes.
Diabetes Self-Management Education (DSME)
| Code | Description | Rate | Coverage |
|---|---|---|---|
| G0108 | Diabetes outpatient self-management training, individual, per 30 minutes | ~$60–$75 | Medicare, most commercial payers |
| G0109 | Diabetes outpatient self-management training, group, per 30 minutes | ~$15–$25 per patient | Medicare, most commercial payers |
Medicare DSME coverage:
- Initial: 10 hours of training (9 hours group + 1 hour individual) in the first year of diagnosis or first time a patient seeks DSME services
- Continuing: 2 hours per year thereafter
- Patient must have a diabetes diagnosis (E10, E11, E13, or other specified diabetes codes)
- DSME must be provided by an accredited program — either in your practice with an accredited program coordinator or through a referral to an accredited DSME provider
- New 2026: Telehealth delivery of DSME is now supported — bill with POS 10 (patient’s home) and Modifier 93 for audio-only or appropriate telehealth modifier for audio-visual visits
Medical Nutrition Therapy (MNT)
| Code | Description | Rate |
|---|---|---|
| 97802 | Medical nutrition therapy, initial assessment and intervention, individual, per 30 minutes | ~$50–$70 |
| 97803 | Medical nutrition therapy, reassessment and intervention, individual, per 30 minutes | ~$45–$60 |
| 97804 | Medical nutrition therapy, group, per 30 minutes | ~$15–$25 per patient |
MNT coverage rules:
- Must be provided by a Registered Dietitian (RD) — physicians cannot bill these codes
- Medicare covers MNT for diabetes and renal disease
- Referral must come from the treating physician — document the referral in the patient chart
- MNT and DSME cannot be billed on the same day for the same patient under Medicare
Part 6: Chronic Care Management in Endocrinology
Chronic Care Management (CCM) is one of the highest-value and most underutilized billing opportunities in endocrinology. Virtually every endocrinology practice has eligible patients.
| Code | Service | Monthly Time | Rate |
|---|---|---|---|
| 99490 | CCM — first 20 minutes | 20 minutes | ~$62/month |
| +99439 | CCM — each additional 20 minutes | 20 minutes | ~$47/month |
| 99487 | Complex CCM — first 60 minutes | 60 minutes | ~$130/month |
| +99489 | Complex CCM — each additional 30 minutes | 30 minutes | ~$65/month |
CCM eligibility in endocrinology: Any patient with two or more chronic conditions expected to last at least 12 months qualifies. In endocrinology, this is an extremely low bar — a patient with Type 2 diabetes and hypothyroidism, or diabetes and hypertension, qualifies immediately.
Requirements:
- Patient must provide written consent at the time of enrollment
- A comprehensive care plan must be documented
- Monthly contact must be maintained — at least 20 minutes of care management time per month
- Only one provider may bill CCM per patient per month
Revenue opportunity: A practice with 150 endocrinology patients eligible for CCM billing 99490 monthly at $62 per patient generates over $111,600 in additional annual revenue from care coordination that is already occurring in the practice.
Part 7: Common Modifiers in Endocrinology
| Modifier | When to Use in Endocrinology |
|---|---|
| 25 | E/M billed on the same day as a CGM service, DEXA scan, or in-office procedure |
| 59 | Distinct procedural service — used when two separate procedures are billed on the same day (e.g., FNA + thyroid ultrasound) |
| 26 | Professional component only — when interpreting CGM data or imaging without owning the equipment |
| TC | Technical component only — when the practice owns the equipment but another provider interprets |
| GY | Service statutorily excluded from Medicare coverage — used for obesity-only GLP-1 prescriptions not covered by Medicare Part D |
| GZ | Service expected to be denied as not medically necessary |
| 93 | Synchronous telemedicine service via audio-only — applicable to DSME telehealth in 2026 |
| 91 | Repeat clinical diagnostic laboratory test — used when the same lab is ordered more than once on the same date for legitimate clinical reasons |
Part 8: 2026 Updates in Endocrinology Billing
1. New ICD-10-CM Code E11.A — Type 2 Diabetes in Remission
Effective October 1, 2025 and fully in effect in 2026, E11.A covers Type 2 diabetes without complications in remission. The provider must explicitly document the word “remission” — not “resolved,” “controlled,” or “well-managed.” Train your endocrinologists on this documentation distinction. It matters for code assignment, HCC risk adjustment, and quality metrics.
2. New CPT 99445 — Automated Physiologic Data Collection
New in 2026, CPT 99445 covers automated collection and transmission of physiologic data from remote monitoring devices — directly applicable to CGM platforms that automatically transmit glucose data. Average Medicare allowance approximately $47 per 30-day period. This code is separate from 95251 (interpretation) and works alongside the existing RPM code set.
3. Expanded Medicare CGM Coverage
Medicare expanded CGM coverage eligibility in 2026, broadening access beyond the previously narrower criteria. Practices should review current eligibility thresholds and confirm their CGM ordering documentation reflects the updated coverage criteria. The 6-month in-person or telehealth visit requirement for continued CGM supply coverage remains in effect.
4. Tirzepatide (Zepbound) — Medicare Coverage for Sleep Apnea
As of January 2025, Medicare Part D covers tirzepatide (Zepbound) for obstructive sleep apnea. This is the first GLP-1 AOM covered by Medicare for a non-diabetes, non-cardiovascular indication. For endocrinology practices managing patients with both obesity and sleep apnea, this opens a Medicare-covered prescribing pathway — provided the sleep apnea diagnosis is clearly documented and supported by a sleep study or physician evaluation.
5. 2026 RPM Code Updates — Shorter Duration Windows
The 2026 CPT updates to Remote Patient Monitoring (covered in our Medical Coding Updates 2026 guide) directly apply to endocrinology CGM monitoring programs. The new shorter-duration RPM codes now allow billing for 2–15 day monitoring periods within a 30-day window — meaning endocrinology practices no longer need a full month of data to bill for RPM services alongside CGM interpretation.
6. GLP-1 Prior Authorization Pressure
Commercial payers have significantly tightened prior authorization requirements for GLP-1 medications in 2026, particularly for obesity and weight management indications. Most commercial plans now require:
- Documentation of BMI
- Evidence of prior weight loss attempts (diet, exercise program)
- Comorbidity documentation (diabetes, sleep apnea, cardiovascular disease)
- Step therapy through lower-cost anti-obesity agents (where applicable)
Build GLP-1 prior authorization workflows into your billing process. Prescribing without verifying prior auth approval is one of the leading causes of GLP-1 claim denials.
Part 9: Top Denial Reasons in Endocrinology and How to Fix Them
1. Unspecified Diabetes Codes
Using E11.9 or E10.9 when the record clearly documents a complication — neuropathy, retinopathy, nephropathy, or CKD.
Fix: Remove unspecified diabetes codes from charge capture templates. Build a workflow that requires the coder to review the note for documented complications before defaulting to the unspecified code.
2. Wrong CGM Code Selected
Billing 95251 when the service was actually a device setup (95249) or professional placement (95250), or billing 95249 without confirming patient device ownership.
Fix: Build a CGM billing decision tree into your charge capture workflow. The question “Does the patient own the device?” must be answered before any CGM code is assigned.
3. 95251 Billed Without a Formal Interpretation Note
Billing CGM interpretation without a separate written interpretation and report in the medical record — just referencing that a CGM report was reviewed is not sufficient.
Fix: Create a standardized CGM interpretation note template. Every 95251 claim must be accompanied by a dated, signed interpretation note that identifies glucose patterns, clinical conclusions, and management impact.
4. E/M Billed Same Day as CGM Without Modifier 25
Billing both a 99214 and 95251 on the same date without Modifier 25 on the E/M code.
Fix: Apply Modifier 25 to the E/M code whenever an E/M and a CGM service are billed on the same date. The E/M must document a problem-focused evaluation separate from the CGM review.
5. Thyroid FNA Coded Without Ultrasound Guidance When Guidance Was Used
Billing 10021 (FNA without imaging) when ultrasound guidance was actually used during the procedure.
Fix: Review documentation before coding thyroid FNA. If ultrasound guidance is used, bill 10005. Do not bill 76942 separately — it is included in 10005.
6. GLP-1 Claim Denied — Coverage Mismatch
Prescribing and billing a GLP-1 under an obesity diagnosis when the payer only covers the drug for diabetes or another covered indication.
Fix: Verify every GLP-1 claim against the patient’s covered diagnoses and the payer’s specific formulary. Document the clinical indication clearly in the note. Never use a covered diagnosis to support a drug prescribed for a non-covered indication.
7. DEXA Without Medical Necessity Documentation
DEXA scan billed without a supporting diagnosis code documenting the clinical indication for the scan.
Fix: Every DEXA claim must be accompanied by a specific ICD-10 code reflecting the clinical indication — postmenopausal status, long-term glucocorticoid use, primary hyperparathyroidism, fracture monitoring, or other covered indication. A Z code alone (e.g., Z13.820 for screening) is not sufficient for Medicare DEXA coverage.
8. CCM Billed Without Patient Consent Documentation
CCM claims denied because the patient consent for CCM services was not documented at the time of enrollment.
Fix: Obtain and document written patient consent for CCM before billing the first month. The consent must be in the patient’s medical record. Some payers also require that the consent date appears on the claim.
Part 10: State-Specific Considerations — Illinois and Florida
Illinois — Endocrinology Billing Notes
Illinois has a significant diabetes burden — particularly in the Chicago metropolitan area, where certain communities have disproportionately high rates of Type 2 diabetes and related complications. This translates to high-volume, high-complexity endocrinology practices with substantial CGM billing activity.
Key Illinois-specific billing notes for endocrinology:
- Illinois Medicaid (HealthChoice Illinois MCOs) covers endocrinology E/M services, diabetes management, and CGM services for eligible Medicaid patients. Route all claims to the patient’s MCO — not to HFS fee-for-service. Verify MCO enrollment at every visit through MEDI (medi.illinois.gov).
- CGM billing under Illinois Medicaid MCOs: CGM coverage and prior authorization requirements vary by MCO. Confirm each plan’s prior auth requirements for CGM device ordering before prescribing. Some Illinois MCOs require annual reauthorization for CGM supplies.
- DSME under Illinois Medicaid: Illinois Medicaid covers diabetes self-management education for eligible beneficiaries. Confirm your DSME program has the required accreditation recognized by the MCO before billing G0108 or G0109.
- New ICD-10 code E11.A is applicable to Illinois Medicaid patients — train your coders on the documentation requirements for the remission designation under the updated IAMHP Billing Manual Version 35.0 (November 2025).
- Illinois Medicaid payer IDs for the five HealthChoice Illinois MCOs (Aetna Better Health: 68024, Blue Cross Community Health Plan: MCDIL, CountyCare: 06541, Meridian: MHPIL, Molina: 20934) apply to endocrinology claims in the same way as all other specialties. Always verify with your clearinghouse before first submission.
Florida — Endocrinology Billing Notes
Florida has one of the highest rates of diabetes and obesity in the country, driven in part by its large and growing population, significant senior demographic, and diverse cultural communities with varying dietary patterns and risk factors. This creates a high-demand market for endocrinology services — particularly CGM-intensive diabetes management and GLP-1 therapy.
Key Florida-specific billing notes for endocrinology:
- Florida SMMC 3.0 (MMA MCOs) covers endocrinology services for Medicaid patients. Under SMMC 3.0, virtually all Medicaid patients are in an MCO — file to the patient’s MMA plan, not to AHCA FFS. Verify MCO enrollment at every visit through FMMIS (mymedicaid-florida.com) or Availity.
- CGM prior authorization under Florida MCOs: Most Florida SMMC MMA plans require prior authorization for CGM device initiation and annual renewal. Submit prior auth requests with supporting documentation of uncontrolled diabetes, history of hypoglycemia, and the clinical rationale for CGM vs. standard glucose monitoring.
- GLP-1 prior authorization in Florida: Florida’s large commercial insurer base (Florida Blue, UnitedHealthcare, Humana, Aetna) all have tightened GLP-1 prior authorization requirements in 2026. Florida Blue specifically requires step therapy documentation before approving GLP-1 agents for weight management. Build these workflows into your pre-prescribing process.
- Tirzepatide for sleep apnea (Zepbound): Florida’s large Medicare population creates significant prescribing opportunity for tirzepatide under the newly covered sleep apnea indication. Ensure the sleep apnea diagnosis is clearly documented — Florida Medicare Administrative Contractor (CGS) will audit claims without adequate diagnostic support.
- DEXA scans in Florida: Florida has one of the highest volumes of DEXA scans in the country given its postmenopausal female population. Confirm prior authorization with each Florida MCO before ordering — most SMMC plans require auth for DEXA outside of the standard Medicare screening schedule.
- Timely filing reminders for endocrinology in Florida: Humana’s 90-day timely filing window (the shortest of major Florida payers) applies to endocrinology claims. CGM monthly billing cycles require prompt submission — don’t let month-end billing workflows push Humana claims past the 90-day mark.
What Your Endocrinology Practice Should Do Right Now
Coding and documentation:
- Audit your last 30 diabetes claims and verify every claim uses a complication-specific code rather than E11.9 or E10.9
- Review your active patient list for patients with documented Type 2 diabetes remission — confirm coders know to assign E11.A when “remission” is explicitly documented
- Confirm every 95251 claim in the last 90 days has a corresponding formal CGM interpretation note in the record
- Verify all GLP-1 prescriptions have the correct diagnosis codes tied to each drug’s covered indication
Revenue opportunities being missed:
- Audit your patient panel for CCM eligibility — any patient with two or more chronic endocrine conditions (diabetes + hypothyroidism, diabetes + obesity, etc.) may qualify
- Check whether your CGM platform supports automated data transmission for CPT 99445 billing — if it does, this is new billable revenue in 2026 you may not be capturing
- Review your DSME program status — if you have an accredited DSME program, confirm G0108 and G0109 are being billed for all eligible patient education sessions
- Identify patients with both obesity and sleep apnea who are Medicare beneficiaries — tirzepatide (Zepbound) is now covered for this population
2026 billing system updates:
- Add ICD-10 code E11.A to your diabetes coding reference materials
- Add CPT 99445 to your CGM billing workflow
- Update GLP-1 prior authorization checklists to reflect 2026 commercial payer requirements
- Confirm your DEXA billing includes the clinical indication ICD-10 code on every claim
Final Thoughts
Endocrinology billing in 2026 is defined by three things: the complexity of diabetes complication coding, the precision required in CGM billing, and the rapidly evolving landscape of GLP-1 and anti-obesity medication coverage. Practices that invest in getting these details right — through trained coders, systematic documentation workflows, and current knowledge of payer-specific rules — consistently outperform those operating on outdated billing knowledge.
The revenue opportunities from CCM, CGM remote monitoring, DSME, and the new 99445 code mean that a well-run endocrinology billing operation in 2026 captures significantly more revenue per patient than one simply billing E/M visits.
At ClaimsXperts, endocrinology is one of our core specialty billing areas. We work with endocrinology practices in Illinois, Florida, and across the country on diabetes complication coding accuracy, CGM billing compliance, GLP-1 prior authorization workflows, CCM program setup, and full-cycle revenue cycle management.
Contact us today to learn how ClaimsXperts can strengthen your endocrinology billing operation.
ClaimsXperts is a Revenue Cycle Management company based in Frisco, TX, serving medical practices across the United States. We specialize in medical billing, coding, and insurance credentialing for solo practitioners, group practices, and specialty clinics.